Plain-English translation of NCT07326930 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research follows children being treated for acute lymphoblastic leukemia to understand how Vincristine (a chemotherapy medication) may affect their nerves over time. Researchers want to learn which children are more likely to develop nerve damage from this medication and what might predict these patterns. By tracking symptoms carefully, the study aims to help doctors better protect children's nerve health during treatment.
Vincristine is an important part of leukemia treatment, but it can sometimes cause nerve damage that affects sensation and movement. Doctors don't yet fully understand who will experience this side effect or how to prevent it. This study hopes to identify early warning signs and risk factors so treatment can be adjusted to protect children's nerves.
You likely qualify if…
You likely don't qualify if…
You would complete questionnaires and assessments seven times over the course of your chemotherapy treatment — starting one week after your first Vincristine dose and continuing at regular intervals through your treatment. At the beginning of the study and each time you're assessed, you'll answer questions about any tingling or numbness in your hands or feet, as well as questions about your sleep, mood, nutrition, activity level, and how you're coping. The whole study lasts several months and involves no additional medications or procedures beyond your regular leukemia treatment.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China